MITOCHON

Artificial Mitochondria for Health

Coordinatore	UNIVERSIDAD COMPLUTENSE DE MADRID    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Spain [ES]
Totale costo	1˙378˙000 €
EC contributo	1˙378˙000 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2013-StG
Funding Scheme	ERC-SG
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-12-01   -   2018-11-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSIDAD COMPLUTENSE DE MADRID  Organization address address: AVENIDA DE SENECA 2 city: MADRID postcode: 28040 contact info Titolo: Dr. Nome: Ivan Cognome: Lopez Montero Email: send email Telefono: 0034 91 394 41 28 Fax: 0034 91 394 41 35	ES (MADRID)	hostInstitution	1˙378˙000.00
2	UNIVERSIDAD COMPLUTENSE DE MADRID  Organization address address: AVENIDA DE SENECA 2 city: MADRID postcode: 28040 contact info Titolo: Mrs. Nome: Maribel Cognome: Rodríguez Villa Email: send email Telefono: +34 91 394 6376 Fax: +34 91 394 6382	ES (MADRID)	hostInstitution	1˙378˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Mitochondria are cell organelles that provide the energetic requirements of the body. The majority of cellular ATP is produced by the membrane protein ATP synthase through a proton gradient across the mitochondrial inner membrane. Alterations in ATP synthase biogenesis can result in severe mitochondrial diseases affecting tissues with high energy requirements as brain and muscles. Mitochondrial diseases affect approximately 20 million people in the EU, causing 35 % of deaths during the first year of life of newborns. However, the available therapeutic approaches, are still extremely limited and there is no specific treatment for ATP synthase deficiencies. To improve the treatments currently available for mitochondrial diseases, the project will focus on the realization of artificial mitochondria (AM). Based on artificial lipid vesicles, AM will be fabricated by means of microfluidics methods, a powerful tool able to produce identical replicas of a given bio-inspired membrane-object. ATP synthase will be expressed and assembled within the lipid bilayer by encapsulating cell-free protein expression systems. To test the ability of AM as in-situ energy fabrication systems, targeting-AM will be endocytosed inside cultured cells and ATP synthesis will be triggered by taking advantage of the proton gradient provided by endosomes. Finally, by enclosing other plasmids encoding for diverse proteins, AM can be used as energy-factoring pockets to elicit protein expression just when internalized within cells. This novel approach may constitute an advanced new concept in gene therapy to more effectively create breakthroughs in improving human health.'